Equities

BullFrog AI Holdings, Inc.

BFRG:NAQ

BullFrog AI Holdings, Inc.

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.38
  • Today's Change0.05 / 2.15%
  • Shares traded31.28k
  • 1 Year change-17.36%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence / machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma (HCC), obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.

  • Revenue in USD (TTM)65.00k
  • Net income in USD-6.08m
  • Incorporated2020
  • Employees4.00
  • Location
    BullFrog AI Holdings, Inc.325 Ellington Blvd, Unit 317GAITHERSBURG 20878United StatesUSA
  • Phone+1 (240) 658-6710
  • Fax+1 (302) 531-3150
  • Websitehttps://www.bullfrogai.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mira Pharmaceuticals Inc0.00-12.78m17.29m3.00--7.79-----0.8562-0.85620.000.15010.00----0.00-373.77---737.47-------------3.170.00-------69.77------
Evaxion Biotech A/S - ADR278.00k-15.21m17.40m49.00--13.47--62.58-36.98-36.980.10480.23160.0174--0.34935,673.47-95.08-100.11-126.11-131.65-----5,469.42-131,560.30----0.8933------4.51--65.53--
NRX Pharmaceuticals Inc0.00-24.83m17.41m2.00---------1.62-1.620.00-1.700.00-------197.97-120.57---168.40-----------189.12--------24.14------
Synlogic Inc3.17m-56.16m17.54m6.00--1.10--5.53-7.24-7.240.35491.370.0628----528,333.30-111.31-40.57-131.17-43.82-----1,771.74-3,245.93----0.00--185.685.9913.40---48.05--
Matinas BioPharma Holdings Inc0.00-22.91m17.66m32.00--0.9243-----5.10-5.100.003.810.00----0.00-78.48-44.62-85.80-48.25-------2,344.60----0.001---65.6255.71-9.26---16.46--
BioVie Inc0.00-37.18m17.74m18.00--0.9342-----9.63-9.630.003.100.00----0.00-94.32-456.35-149.75-1,810.88------------0.2969-------92.67------
Athira Pharma Inc0.00-113.45m17.80m65.00--0.2136-----2.97-2.970.002.170.00----0.00-71.06-30.73-83.81-32.46------------0.00-------23.04------
Cocrystal Pharma Inc0.00-17.93m17.80m12.00--1.02-----1.76-1.760.001.710.00----0.00-61.98-50.94-66.88-52.77-------1,501.78----0.00------53.69--33.34--
Lyra Therapeutics Inc1.82m-101.39m17.92m87.00--0.5783--9.84-1.61-1.610.02940.47330.0165----20,681.82-92.07-58.01-108.51-68.69-----5,570.88-6,235.31----0.00--14.314.60-13.39--95.14--
Sol Gel Technologies Ltd6.56m-14.92m18.04m36.00--0.5169--2.75-0.5354-0.53540.23551.250.1351--1.59182,194.40-30.72-31.60-34.59-35.49-----227.40-135.76----0.00---59.9864.50-82.52---33.78--
Bullfrog AI Holdings, Inc.65.00k-6.08m18.29m4.00--3.40--281.41-0.8441-0.84410.0090.68600.0107----16,250.00-100.10---117.94--92.00---9,331.34-----328.510.0596--550.00---91.11------
Biomx Inc0.00-26.25m18.36m58.00---------0.4575-0.45750.000.39290.00----0.00-47.79---57.76--------------0.00------7.59------
Finch Therapeutics Group Inc0.00-14.17m18.40m18.00--1.29-----8.82-8.820.008.860.00-------25.20---28.80--------------0.00---87.57--34.80------
Spruce Biosciences Inc9.57m-43.11m18.49m22.00--0.3124--1.93-1.05-1.050.23381.430.095----330,069.00-42.79-41.24-52.43-46.49-----450.38-1,774.39---117.260.0412-------3.77------
Brainstorm Cell Therapeutics Inc0.00-12.75m18.98m29.00---------0.2242-0.22420.00-0.04430.00----0.00-223.03-117.19---231.65--------------------29.18---45.34--
Data as of Sep 19 2024. Currency figures normalised to BullFrog AI Holdings, Inc.'s reporting currency: US Dollar USD

Institutional shareholders

3.86%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 2024124.15k1.58%
Fortem Financial Group LLCas of 30 Jun 202453.30k0.68%
Geode Capital Management LLCas of 30 Jun 202427.73k0.35%
Virtu Americas LLCas of 30 Jun 202427.19k0.35%
Renaissance Technologies LLCas of 30 Jun 202419.80k0.25%
XTX Markets LLCas of 30 Jun 202418.58k0.24%
Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Jun 202415.00k0.19%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 20247.48k0.10%
Tower Research Capital LLCas of 30 Jun 20246.16k0.08%
UBS Securities LLCas of 30 Jun 20243.52k0.05%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.